- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: AZD5991 is an oncology clinical lead. Structurally it is a BH3 mimetic that inhibits function of the MCL1 apoptosis regulator protein (Mcl-1) and induces apoptosis [1-2]. AZD5991 was designed by AstraZeneca for potential to treat haematologic malignancies such as chronic lymphocytic leukemia and multiple myeloma.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|CAS Registry No.
|2143061-82-7 (source: PubChem)
|GtoPdb PubChem SID
|RCSB PDB Ligand
|Search Google for chemical match using the InChIKey
|Search Google for chemicals with the same backbone
|UniChem Compound Search for chemical match using the InChIKey
|UniChem Connectivity Search for chemical match using the InChIKey